5-(4-bromophenyl)pyrimidine-4,6-diol | CAS:706811-25-8

We serve 5-(4-bromophenyl)pyrimidine-4,6-diol CAS:706811-25-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
5-(4-bromophenyl)pyrimidine-4,6-diol

Chemical Name:5-(4-bromophenyl)pyrimidine-4,6-diol
CAS.NO:706811-25-8
Synonyms:5-(4-bromophenyl)pyrimidine-4,6-diol
5-(4-bromophenyl)-pyrimidine-4,6-diol
Oxazole,5-(4-bromophenyl)
5-(4-bromophenyl)-oxazole
5-(4-Bromophenyl)-6-hydroxy-4(1H)-pyrimidinone
 
Physical and Chemical Properties:
Density 1.7±0.1 g/cm3
Boiling Point 429.6±45.0 °C at 760 mmHg
Molecular Formula C10H7BrN2O2
Molecular Weight 267.079
Flash Point 213.6±28.7 °C
 
Specification:
Appearance:White powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of macitentan.



Contact us for information like 5-(4-bromophenyl)pyrimidine-4,6-diol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-(4-Bromophenyl)-6-hydroxy-4(1H)-pyrimidinone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-(4-bromophenyl)-pyrimidine-4,6-diol Use and application,5-(4-Bromophenyl)-6-hydroxy-4(1H)-pyrimidinone technical grade,usp/ep/jp grade.


Related News: FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus.5-Ethyl-2-pyridineethanol manufacturer Both were in Siberia, and both are Chinese nationals who had recently traveled to China.1,2,4-Trifluorobenzene supplier Both were in Siberia, and both are Chinese nationals who had recently traveled to China.4-isothiocyanatobenzonitrile vendor In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.